SA-13353

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameSA-13353
Drug Alias NameDE-096SA-13353
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsDiabetic macular oedemaArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSanten Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAyumiSanten
Active IndicationsN/A
Inactive IndicationsDiabetic macular oedemaArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A